Regulatory Update

Weekly Regulatory News

This week in medical device regulatory news, EU parliament moves toward a revision of the EU MDR, the UK enhances post-market surveillance requirements, US FDA prioritizes guidance revisions for 2025, and more.

Published on:
November 6, 2024

EUROPE

EU Commission Updates Harmonized Standards for Healthcare Products

The EU Commission has revised its list of harmonized standards, including new updates relevant to aseptic processing and clinical study practices. Significant updates in this revision include:

  • EN ISO 13408-1:2024 - “Aseptic Processing of Healthcare Products - Part 1: General Requirements,” which provides updated guidelines for aseptic processing (aligned with ISO 13408-1:2023).
  • EN ISO 20916:2024 - “In Vitro Diagnostic Medical Devices – Clinical Performance Studies Using Specimens from Human Subjects – Good Study Practice.” This update introduces specific annexes that link requirements to the IVDR sections, although no changes were made to the ISO 20916 standard itself.

These changes were published under Commission Implementing Decision (EU) 2024/2631 on October 8, 2024, as an amendment to Implementing Decision (EU) 2021/1182. For more details, visit Commission Decision 2024/2631 and Commission Decision 2024/2625.  

EU Parliament Motion Urges Revision of Medical Devices Regulation (2024/2849(RSP))  

The European Parliament has issued a Joint Motion for a Resolution calling for an urgent revision of the Medical Devices Regulation (MDR), following a formal re-evaluation of EU regulations. This non-binding motion, supported by several parliamentary groups (EPP, S&D, ECR, Renew Europe, Verts/ALE), stems from discussions within the Medical Devices Coordination Working Group (MDCG), where the EU Commission outlined its strategy for the further evaluation of the MDR and IVDR.

The motion serves as a call to action for specific categories of medical devices and encourages the EU Commission to reconsider its priorities for regulatory improvements. However, the resolution is broad and general, without specifying concrete actions or solutions, and does not signal a major overhaul of the current framework. It is important to note that while the motion highlights areas of concern, it should not be viewed as a call for delay or as a sign of significant unresolved issues within the EU’s current regulations.

For more information on the resolution, visit European Parliament Motion and Parliament Procedure.

Revision of ISO/IEC 16022 and ISO/IEC 15415 Enhances Barcode Identification for UDI Compliance

The updated ISO/IEC 16022:2024 and ISO/IEC 15415:2024 standards, released in 2024, focus on improving barcode identification techniques for Unique Device Identification (UDI). ISO/IEC 16022:2024 details the Data Matrix barcode symbology, while ISO/IEC 15415:2024 specifies print quality testing for 2D barcodes. Key updates include the introduction of a new print quality parameter, "print growth," and a seamless link between both standards, aligning continuous grading with all quality measurements. These revisions ensure better barcode readability and verification, crucial for UDI compliance in the medical device industry.

For more details, visit:

EU Launches Initiative for Master UDI to Group Spectacle Frames, Lenses, and Reading Glasses

The EU is introducing a new initiative to streamline the Unique Device Identification (UDI) system for certain medical devices. To reduce the complexity of assigning multiple identifiers to similar products, such as spectacle frames, lenses, and ready-made reading glasses, these devices will now fall under a single identifier, the "Master UDI-DI." This approach aims to improve regulatory efficiency while maintaining the ability to trace devices when needed, enhancing safety without unnecessary duplication of identifiers.

EU Introduces New Obligation for Manufacturers to Inform About Supply Interruptions or Discontinuations

The EU Commission has published a new Q&A document outlining the obligation for Medical Device and IVD manufacturers to inform about supply interruptions or discontinuations. This requirement, introduced by Regulation (EU) 2024/1860 under MDR/IVDR Article 10(a), mandates manufacturers to notify economic operators, competent authorities, and/or EU Authorized Representatives within specified timelines. The new obligation, effective from January 10, 2025, emphasizes the need for manufacturers to update their internal QMS processes to ensure compliance in case of supply disruptions.

Learn more about EU Medical Device Registration.

SWITZERLAND

Reminder: Swissdamed Data Validation Deadline for Swissmedic Registrants - 13 November 2024

Swissmedic is reminding all economic operators registered with a CHRN to validate their migrated data on Swissdamed by 13 November 2024. Operators are encouraged to take just ten minutes to verify their company details and the data of each individual registered actor to ensure accuracy. This validation is a critical step for compliance, and all remaining operators must complete this task by the deadline.

Swissmedic Annual Report Highlights Need for Improvement in Hospital Medical Device Inspections

Swissmedic's annual report, published on October 7, 2024, reveals concerning findings from inspections of 25 hospitals in 2023. The report emphasizes the need for improvements in quality management, maintenance, staff training, and infrastructure within reprocessing departments. Despite previous warnings in 2021/2022, no significant improvements were observed. Swissmedic concluded that the identified deficiencies pose risks to device safety and patient health. Moving forward, Swissmedic will intensify monitoring and collaborate with experts to develop binding guidelines for improving quality assurance in hospitals.

Swissmedic Publishes Corrigendum for Good Practice in Reprocessing Medical Devices

On October 3, 2024, Swissmedic issued a corrigendum for the "Good Practice for the Reprocessing of Medical Devices" (GPA), developed in collaboration with the Swiss Society for Sterile Materials Provision (SGSV) and the Swiss Society for Hospital Hygiene (SGSH). The updated guidelines clarify regulatory requirements for medical device manufacturers and healthcare institutions involved in reprocessing medical devices, including compliance with Article 71 of the MedDO. The corrigendum extends these requirements beyond central sterilization departments to include surgical areas, endoscopy departments, and nursing services, potentially signaling increased scrutiny for hospitals, in light of findings from Swissmedic's recent inspection report.

Learn more about Switzerland Medical Device Registration.

UNITED KINGDOM

New UK Statutory Instrument Introduces Enhanced Post-Market Surveillance for Medical Devices

On October 22, 2024, the MHRA laid a Statutory Instrument (SI) in Parliament, marking the first step in Great Britain’s medical device regulatory reform. This SI focuses on strengthening post-market surveillance (PMS) requirements, enhancing patient and public safety in alignment with international standards. This update follows MHRA’s 2021 consultations on the future of UK medical device regulation. While closely aligned with EU MDR/IVDR PMS requirements, the SI will primarily impact manufacturers applying for UKCA marking directly, who must adapt their Quality Management Systems accordingly. Full legislative changes are expected to take effect in 2025.

Learn more about MHRA UK Medical Device Registration & Approval.

UNITED STATES

FDA CDRH Releases Priority Guidance List for Medical Devices in Fiscal Year 2025

The FDA’s Center for Devices and Radiological Health (CDRH) has published its proposed guidance list for fiscal year 2025, outlining planned updates and inviting feedback on potential revisions. This list is organized as follows:

  • A-list: High-priority guidance documents CDRH plans to publish in FY 2025, including topics such as:
  • Artificial Intelligence (AI)
  • Cybersecurity
  • Lab-Developed Tests (LDTs)
  • In Vitro Diagnostic (IVD) labeling
  • Emergency Use Authorization (EUA)
  • Q-Submission Program
  • B-list: Secondary-priority guidance documents that CDRH intends to publish if resources permit.
  • "Under Construction" list: Guidance documents that CDRH aims to develop as resources allow, not yet assigned to A or B lists.
  • Retrospective review list: Includes guidance documents issued in 1985, 1995, 2005, and 2015, which CDRH will review to ensure they reflect the agency’s current thinking.

This list is valuable for medical device manufacturers to anticipate regulatory changes and prepare for future requirements.

FDA Issues Guidance on Performance Criteria for Dental Cements in Safety and Performance Based Pathway  

On September 30, 2024, the FDA published new guidance on performance criteria for dental cements under the Safety and Performance Based Pathway. This guidance allows manufacturers to demonstrate substantial equivalence through FDA-recommended performance criteria rather than direct comparisons with predicate devices. Aimed at promoting consistency, this approach streamlines the review process for dental cements, ensuring a more efficient pathway for premarket submissions.

Learn more about FDA US Medical Device Registration.

Subscribe to newsletter
Subscribe to receive the latest blog posts to your inbox every week.
By subscribing, you agree to our Terms and Conditions.
Thank you for subscribing!
Oops! Something went wrong while submitting the form.
Read more

Latest News

Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.

An extensive round-up of medical device regulatory news from November 2024 includes new and updated guidance documents, Q&As, and directives from Europe and the US, including the new EU Product Liability Directive for AI and Smart Products.

Pure Global is proud to announce its inclusion in the China Business Service Providers (BSP) directory on the International Trade Administration website.

Regulatory Update
November 20, 2024

This week in medical device regulatory news, Thailand has introduced new refer and transfer guidelines, Europe released an updated Q&A on IVDR and MDR vigilance terms, and Romania has new rules for Economic Operators.

Regulatory Update
November 13, 2024

This week, we bring you medical device regulatory update coverage from around the world, including new registration Q&A resources in Taiwan and Japan, UK relaunches ILAP pathway, Mexico will apply a new acquisition model, and more.

Contact us
Request information

Let's Talk,
Anywhere You Are.

Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.

Our closest representative will get back to you within 24 hours.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Latest Blog Content

Explore our collection of articles, success stories, and regulatory updates, designed to help you take your product global.

Risk increases compliance chalenges under IVDR
Blog Article
What are the challenges under IVDR?

IVD manufacturers cite the new classification system, detailed definitions for intended purposes, and the need for verification of clinical evidence as key challenges under the IVDR.

Blog Article
EU Parliament Revises MDR and IVDR

On October 23, the European Parliament adopted a resolution revising specific elements of the Medical Devices Regulation (MDR) and the In Vitro Diagnostic Devices Regulation (IVDR). This resolution intends to address ongoing challenges in implementing the regulations by 2025 and to improve patient access to important medical products.

Blog Article
Language Challenges in MedTech Going Global and Our Solution

Multilingual documentation presents ongoing compliance and logistical hurdles for MedTech manufacturers. Transla.Ai is an industry-specific translation tool that can accelerate and streamline the translation process.

Medical device supply chain
Blog Article
Managing your medical device supply chain

The connection between supplier controls and business risks is becoming increasingly evident. In this article, we discuss perspectives on how to maintain a compliant medical device supply chain.